Sign in
4

Changes in Ownership

Keros Therapeutics, Inc. Filed Acc 0001209191-24-001155

Chief Financial Officer sold 40,000 shares at $45.29 ($1,811,600)

  • Chief Financial Officer acquired 40,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Regnante Keith Chief Financial Officer 2023-11-04 Option exercise +40,000 $16.00 $640,000 40,000 D
Regnante Keith Chief Financial Officer 2023-11-04 Sale −40,000 $45.29 $1,811,600 0 D
Derivatives
Regnante Keith Chief Financial Officer 2024-01-04 Option exercise · Employee Stock Option (right to buy) −40,000 53,622 D
Open-market sales · 40,000 sh · avg $45.29 · $1,811,600
Loading xslF345X05/doc4.xml…